div class=trans-pagebutton class=gotoPage data-page=1Page 1button div class=trans-imageimg data-url=documentsoc-iecas-evolocumab-e-o-232-632-283-ole-234-116-624-232-ole-440-438-212-ole-153htmlpage=1 data-page=1 class=trans-thumb lazyload alt=Page 1: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mM8Uw8AAh0BTZud3BwAAAAASUVORK5CYII= data-src=https:reader034fdocumentsusreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails1jpg width=140 height=200 divdivdiv class=trans-pagebutton class=gotoPage data-page=2Page 2button div class=trans-imageimg data-url=documentsoc-iecas-evolocumab-e-o-232-632-283-ole-234-116-624-232-ole-440-438-212-ole-153htmlpage=2 data-page=2 class=trans-thumb lazyload alt=Page 2: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mM8Uw8AAh0BTZud3BwAAAAASUVORK5CYII= data-src=https:reader034fdocumentsusreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails2jpg width=140 height=200 divdivdiv class=trans-pagebutton class=gotoPage data-page=3Page 3button div class=trans-imageimg data-url=documentsoc-iecas-evolocumab-e-o-232-632-283-ole-234-116-624-232-ole-440-438-212-ole-153htmlpage=3 data-page=3 class=trans-thumb lazyload alt=Page 3: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mM8Uw8AAh0BTZud3BwAAAAASUVORK5CYII=...